<h3>提升您的投资策略：</h3>
<ul>
<li>享受 TipRanks Premium 50% 的折扣！解锁强大的投资工具、先进的数据和专家分析师的见解，帮助您自信投资。</li>
</ul>
<p>来自 EuroEyes International Eye Clinic Limited (HK:1846) 的最新更新已发布。</p>
<p>EuroEyes International Eye Clinic Limited 宣布通过其子公司收购瑞士和英国的资产。这些收购包括用于屈光手术的医疗诊所及相关资产，瑞士资产估值为 12,010,000 瑞士法郎，英国资产估值为 200,000 瑞士法郎。这些交易根据香港证券交易所上市规则被视为可披露的，表明 EuroEyes 在欧洲的运营能力和市场存在的战略扩张。</p>
<p>(HK:1846) 股票的最新分析师评级为持有，目标价格为 3.50 港元。要查看 EuroEyes International Eye Clinic Limited 股票的完整分析师预测列表，请参见 HK:1846 股票预测页面。</p>
<p><strong>关于 EuroEyes International Eye Clinic Limited 的更多信息</strong></p>
<p>EuroEyes International Eye Clinic Limited 在医疗行业运营，专注于提供屈光手术服务。该公司专门从事眼科护理，特别是矫正眼科手术，并在欧洲，包括瑞士和英国，拥有市场存在。</p>
<p><strong>平均交易量：</strong> 166,536</p>
<p><strong>技术情绪信号：</strong> 卖出</p>
<p><strong>当前市值：</strong> 943.3M 港元</p>
<p>在 TipRanks 的股票分析页面上找到 1846 股票的详细分析。</p>
<h2>热门文章：</h2>
<ul>
<li>CAPR 诉讼警报！针对 Capricor Therapeutics 的集体诉讼</li>
<li>META 或 GOOGL：顶级分析师选择的 “顶级消费 AI 投资”</li>
<li>特斯拉在中国将新款 Model 3 价格下调 4%，而挪威销量激增 38%</li>
</ul>
<p>免责声明与披露报告问题</p>

德视佳

<p>欧睿眼科国际诊所有限公司 (HK:1846) 宣布在瑞士和英国进行战略收购，分别收购了价值 12,010,000 瑞士法郎和 200,000 瑞士法郎的医疗诊所和屈光手术资产。这些交易根据香港证券交易所上市规则需披露，标志着欧睿在欧洲运营能力的显著扩展。HK:1846 的最新分析师评级为持有，目标价格为 3.50 港元。欧睿专注于眼科护理和矫正手术，目前市值为 943.3 百万港元</p>

<h3>Elevate Your Investing Strategy:</h3>
<div class="lb-trans"><h3>提升您的投资策略：</h3>
</div><ul>
<li>Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.</li>
</ul>
<div class="lb-trans"><ul>
<li>享受 TipRanks Premium 50% 的折扣！解锁强大的投资工具、先进的数据和专家分析师的见解，帮助您自信投资。</li>
</ul>
</div><p>The latest update is out from EuroEyes International Eye Clinic Limited ( (HK:1846) ).</p>
<div class="lb-trans"><p>来自 EuroEyes International Eye Clinic Limited (HK:1846) 的最新更新已发布。</p>
</div><p>EuroEyes International Eye Clinic Limited has announced the acquisition of assets in Switzerland and the United Kingdom through its subsidiaries. The acquisitions include medical clinics and related assets for refractive surgery, with the Swiss assets valued at CHF12,010,000 and the UK assets at CHF200,000. These transactions are considered discloseable under the Hong Kong Stock Exchange Listing Rules, indicating a strategic expansion in EuroEyes’ operational capacity and market presence in Europe.</p>
<div class="lb-trans"><p>EuroEyes International Eye Clinic Limited 宣布通过其子公司收购瑞士和英国的资产。这些收购包括用于屈光手术的医疗诊所及相关资产，瑞士资产估值为 12,010,000 瑞士法郎，英国资产估值为 200,000 瑞士法郎。这些交易根据香港证券交易所上市规则被视为可披露的，表明 EuroEyes 在欧洲的运营能力和市场存在的战略扩张。</p>
</div><p>The most recent analyst rating on (HK:1846) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on EuroEyes International Eye Clinic Limited stock, see the HK:1846 Stock Forecast page.</p>
<div class="lb-trans"><p>(HK:1846) 股票的最新分析师评级为持有，目标价格为 3.50 港元。要查看 EuroEyes International Eye Clinic Limited 股票的完整分析师预测列表，请参见 HK:1846 股票预测页面。</p>
</div><p><strong>More about EuroEyes International Eye Clinic Limited</strong></p>
<div class="lb-trans"><p><strong>关于 EuroEyes International Eye Clinic Limited 的更多信息</strong></p>
</div><p>EuroEyes International Eye Clinic Limited operates in the healthcare industry, focusing on providing refractive surgery services. The company specializes in eye care, particularly in corrective eye surgeries, and has a market presence in Europe, including Switzerland and the United Kingdom.</p>
<div class="lb-trans"><p>EuroEyes International Eye Clinic Limited 在医疗行业运营，专注于提供屈光手术服务。该公司专门从事眼科护理，特别是矫正眼科手术，并在欧洲，包括瑞士和英国，拥有市场存在。</p>
</div><p><strong>Average Trading Volume:</strong> 166,536</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 166,536</p>
</div><p><strong>Technical Sentiment Signal:</strong> Sell</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 卖出</p>
</div><p><strong>Current Market Cap:</strong> HK$943.3M</p>
<div class="lb-trans"><p><strong>当前市值：</strong> 943.3M 港元</p>
</div><p>Find detailed analytics on 1846 stock on TipRanks’ Stock Analysis page.</p>
<div class="lb-trans"><p>在 TipRanks 的股票分析页面上找到 1846 股票的详细分析。</p>
</div><h2>Trending Articles:</h2>
<div class="lb-trans"><h2>热门文章：</h2>
</div><ul>
<li>CAPR Lawsuit Alert! Class Action Lawsuit Against Capricor Therapeutics</li>
<li>META or GOOGL: Top Analyst Picks the ‘Top Consumer AI Play’</li>
<li>Tesla Cuts New Model 3 Prices by 4% in China, While Norway Sales Surge 38%</li>
</ul>
<div class="lb-trans"><ul>
<li>CAPR 诉讼警报！针对 Capricor Therapeutics 的集体诉讼</li>
<li>META 或 GOOGL：顶级分析师选择的 “顶级消费 AI 投资”</li>
<li>特斯拉在中国将新款 Model 3 价格下调 4%，而挪威销量激增 38%</li>
</ul>
</div><p>Disclaimer &amp; DisclosureReport an Issue</p>
<div class="lb-trans"><p>免责声明与披露报告问题</p>
</div>

德视佳通过战略收购扩大其在欧洲的业务